drugset / Trial / NCT04035603

Multimodal Cue Exposure Therapy for Smoking Cessation

NCT04035603

RandomizedParallel-groupQuadruple-blindTreatment

Summary

At two sites (Boston University and the University of Texas at Austin, under the MPI direction of Drs. Otto and Smits) the investigators propose to randomly assign 240 adult smokers who have achieved short-term abstinence following open treatment with a 4 session cognitive-behavior therapy program combined with medication (nicotine patch, varenicline, or bupropion, selected openly) to (1) d-cycloserine augmentation of multimodal cue exposure therapy (CET), or (2) placebo augmentation of multimodal CET. This Stage II project is designed to: (1) evaluate the short-term and long-term efficacy of the experimental intervention, (2) further test putative mechanisms of change, (3) explore possible moderator effects of theoretically-relevant variables, and (4) use innovative, multimodal CET strategies. Putative mediators and smoking abstinence will be assessed during the intervention period and up to 6 months following the quit attempt.

Timeline

Start
2020-10-01
Primary completion
2021-01-31
Completion
2021-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 50 mg
Background Bupropion Small molecule
Background Nicotine Unknown
Background Varenicline Small molecule

Indications

No indication recorded.